suberoyl bis-hydroxamic acid has been researched along with Leukemia in 2 studies
suberoyl bis-hydroxamic acid: antineoplastic, Histone Deacetylase inhibitor
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Salmi-Smail, C | 1 |
| Fabre, A | 1 |
| Dequiedt, F | 1 |
| Restouin, A | 1 |
| Castellano, R | 1 |
| Garbit, S | 1 |
| Roche, P | 1 |
| Morelli, X | 1 |
| Brunel, JM | 1 |
| Collette, Y | 1 |
| Chen, S | 1 |
| Dai, Y | 1 |
| Pei, XY | 1 |
| Grant, S | 1 |
2 other studies available for suberoyl bis-hydroxamic acid and Leukemia
| Article | Year |
|---|---|
Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
Topics: Animals; Antineoplastic Agents; Blood Cell Count; Cell Line, Tumor; Drug Screening Assays, Antitumor | 2010 |
Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-X Protein; Biphenyl Compounds; | 2009 |